UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011862
Receipt number R000013865
Scientific Title Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes
Date of disclosure of the study information 2013/10/02
Last modified on 2014/03/25 13:00:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Acronym

Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Scientific Title

Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Scientific Title:Acronym

Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetes

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Study of the usefulness of selective DPP-4 inhibitor Vildagliptin for patients with type 2 diabetes who is inadequate glycemic controll by sitaguliptin(50mg/day).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Surrogate marker(inflammation and oxidative stress)
Continuous Glucose Monitoring

Key secondary outcomes

HbA1c


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Vildagliptin

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients with type 2 diabetes inadequately controlled with sitaguliptin
HbA1c(NGSP) of >= 7.0%
2)Patients with type 2 diabetes treated by diet and exercise therapy
3)Given informed consent

Key exclusion criteria

1)Under insulin treatment (diabetic ketoacidosis , diabetic coma , type 1 diabetes , etc)
2)Has allergy to vildagliptin
3)Severe liver dammge
4)After severe infection,operation or injury
5)Patient who was considered to be appropriate to this study by attending physician

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Osonoi

Organization

Naka Kinen Clinic

Division name

Director

Zip code


Address

745-5,Nakadai,Naka-city,Ibaraki,311-0113,Japan

TEL

029-353-2800

Email

t-osonoi@kensei-kai.com


Public contact

Name of contact person

1st name
Middle name
Last name Kensuke Ofuchi

Organization

Naka Kinen Clinic

Division name

Clinical Laboratory

Zip code


Address

745-5,Nakadai,Naka-city,Ibaraki,311-0113,Japan

TEL

029-353-2800

Homepage URL


Email

k-ofuchi@kensei-kai.com


Sponsor or person

Institute

Naka Kinen Clinic

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Faculty of Life and Environmental Sciences,University of Yamanashi

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

那珂記念クリニック(茨城県)


Other administrative information

Date of disclosure of the study information

2013 Year 10 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 03 Month 14 Day

Date of IRB


Anticipated trial start date

2013 Year 10 Month 10 Day

Last follow-up date

2014 Year 03 Month 18 Day

Date of closure to data entry

2014 Year 04 Month 10 Day

Date trial data considered complete

2014 Year 04 Month 30 Day

Date analysis concluded

2014 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 09 Month 25 Day

Last modified on

2014 Year 03 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013865


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name